2021
Update on gout management: what is old and what is new
Afinogenova Y, Danve A, Neogi T. Update on gout management: what is old and what is new. Current Opinion In Rheumatology 2021, 34: 118-124. PMID: 34907116, PMCID: PMC8799507, DOI: 10.1097/bor.0000000000000861.Peer-Reviewed Original ResearchConceptsUrate-lowering therapyRisk factorsAdjunctive management strategiesUrate-lowering efficacyChronic kidney diseaseUse of allopurinolAllopurinol hypersensitivity syndromeManagement of hyperuricemiaCrystal-Associated Disease NetworkPopulation attributable riskEvidence-based recommendationsComprehensive evidence-based recommendationsNew drug therapiesGout guidelinesCause mortalityHypersensitivity syndromeCardiovascular riskGout flaresGout managementKidney diseaseDrug therapyFlare managementAttributable riskDietary factorsSerum urate
2020
2020 American College of Rheumatology Guideline for the Management of Gout
FitzGerald JD, Dalbeth N, Mikuls T, Brignardello‐Petersen R, Guyatt G, Abeles AM, Gelber AC, Harrold LR, Khanna D, King C, Levy G, Libbey C, Mount D, Pillinger MH, Rosenthal A, Singh JA, Sims JE, Smith BJ, Wenger NS, Bae SS, Danve A, Khanna PP, Kim SC, Lenert A, Poon S, Qasim A, Sehra ST, Sharma TSK, Toprover M, Turgunbaev M, Zeng L, Zhang MA, Turner AS, Neogi T. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis & Rheumatology 2020, 72: 879-895. PMID: 32390306, DOI: 10.1002/art.41247.Peer-Reviewed Original ResearchConceptsUrate-lowering therapyManagement of goutGout flaresFirst-line urate-lowering therapyInitiation of ULTSevere chronic kidney diseaseFrequent gout flaresLower starting doseSerum urate measurementsChronic kidney diseaseNonsteroidal antiinflammatory drugsTarget management strategyConsensus processRheumatology guidelinesSU targetDose titrationRecommendations AssessmentStarting doseProphylaxis therapyRadiographic damageGRADE methodologyTophaceous goutKidney diseasePatient preferencesAntiinflammatory drugs2020 American College of Rheumatology Guideline for the Management of Gout
FitzGerald JD, Dalbeth N, Mikuls T, Brignardello‐Petersen R, Guyatt G, Abeles AM, Gelber AC, Harrold LR, Khanna D, King C, Levy G, Libbey C, Mount D, Pillinger MH, Rosenthal A, Singh JA, Sims JE, Smith BJ, Wenger NS, Bae SS, Danve A, Khanna PP, Kim SC, Lenert A, Poon S, Qasim A, Sehra ST, Sharma TSK, Toprover M, Turgunbaev M, Zeng L, Zhang MA, Turner AS, Neogi T. 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care & Research 2020, 72: 744-760. PMID: 32391934, PMCID: PMC10563586, DOI: 10.1002/acr.24180.Peer-Reviewed Original ResearchConceptsUrate-lowering therapyManagement of goutGout flaresFirst-line urate-lowering therapyInitiation of ULTSevere chronic kidney diseaseFrequent gout flaresLower starting doseSerum urate measurementsChronic kidney diseaseNonsteroidal antiinflammatory drugsTarget management strategyConsensus processRheumatology guidelinesSU targetDose titrationRecommendations AssessmentStarting doseProphylaxis therapyRadiographic damageGRADE methodologyTophaceous goutKidney diseasePatient preferencesAntiinflammatory drugs
2018
AB0538 Increased body mass index may not be a risk factor for the development of lupus nephritis
Chock Y, Danve A, School of Medicine O, Petri M, Fu W. AB0538 Increased body mass index may not be a risk factor for the development of lupus nephritis. Annals Of The Rheumatic Diseases 2018, 77: 1425. DOI: 10.1136/annrheumdis-2018-eular.4524.Peer-Reviewed Original ResearchSystemic lupus erythematosusBody mass indexChronic kidney diseaseLow disease activityLupus nephritisSLE patientsDisease activityComplement levelsMass indexAvailable body mass indexBiopsy-proven lupus nephritisLow-grade inflammatory stateElevated body mass indexRetrospective cross-sectional studyFirst BMI measurementRisk of nephritisCategorical variablesHigher leptin levelsCross-sectional studyHigher complement levelsChi-square testLupus CohortCohort entryObese patientsACR criteria